

## Special Issue

# Mechanisms of Action of Therapies for Multiple Sclerosis

### Message from the Guest Editors

In recent years, the number of treatment options for multiple sclerosis (MS) patients has grown significantly and includes (i) sphingosine 1-phosphate modulators (fingolimod, siponimod, ozanimod and ponesimod), (ii) oral therapies (teriflunomide, dimethyl fumarate), (iii) Bruton's tyrosine kinase inhibitors (evobrutinib and tolebrutinib), and (iv) cell-depleting therapies such as cladribine, anti-CD20 monoclonal antibodies (ocrelizumab, ofatumumab), and anti-CD52 monoclonal antibodies (alemtuzumab). Each of these therapies has a distinct mechanism of action that may explain the beneficial effects of the drug in the disease, ranging from different degrees of immunomodulation to significant cell depletion. Manuscripts addressing the topic of the mechanism of action of the abovementioned therapies for MS are invited for this Special Issue. They can include but should not be restricted to in vitro and ex vivo immunophenotyping studies as well as omics approaches in peripheral blood and cerebrospinal fluid samples from treated MS patients. Studies relating changes in biomarker levels and the therapeutic response to therapies are also welcome.

---

### Guest Editors

Dr. Manuel Comabella

Neurology Department, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron Hospital, 08035 Barcelona, Spain

Dr. Nicolás Fissolo

Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

---

### Deadline for manuscript submissions

closed (31 August 2022)



## Cells

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 11.4  
Indexed in PubMed



[mdpi.com/si/66461](https://mdpi.com/si/66461)

*Cells*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cells@mdpi.com](mailto:cells@mdpi.com)

[mdpi.com/journal/  
cells](https://mdpi.com/journal/cells)





# Cells

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 11.4  
Indexed in PubMed



[mdpi.com/journal/  
cells](https://mdpi.com/journal/cells)



## About the Journal

### Message from the Editorial Board

*Cells* has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

---

### Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Neuroscience, UMN Twin Cities, 6-145 Jackson Hall, 321 Church St SE,  
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,  
Copenhagen, Denmark

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).